Home
BioComo

BioComo Market Share Analysis for July 2026

バイオコモ株式会社は最先端のベクター技術を駆使して、人類の健康と未来を支える医療ソリューションを創出し、グローバルな感染症・がん治療分野において、革新的技術で世界をリードするバイオ医薬企業を目指します。

Industry: N/A

Domainbiocomo.jp

Year Founded--

Employees51 - 200

Annual Revenue$10M - $15M

BioComo

BioComo (including company regionals)

biocomo.jp

See more website traffic and engagement information

BioComo Revenue up to July 2026 is 10M - 15M

revenue generated by BioComo top domains

BioComo top domains revenue over 3 years

Revenue for BioComo top domains

biocomo.jp10M - 15M

See more with Sales Intelligence

Total visits to BioComo's top domains

Understand BioComo market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

biocomo.jp--

See more with Sales Intelligence

Avg. visit duration in BioComo's top domains

Analyze BioComo engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

biocomo.jp--

See more with Sales Intelligence

Avg. pageviews on BioComo's top domains

See how BioComo keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

biocomo.jp--

See more with Sales Intelligence

BioComo top competitors by domain

Looks like there’s not enough data here

No Data to Display

Top technologies used by BioComo

These are the website technologies, by industry, used by BioComo top domains

Advertising (2)

Google Adsense

Mobile (2)

Meta Viewport

Widget (2)

Twemoji

Audio Video Media (1)

YouTube

More Technologies

3

See all

News & Signals from BioComo

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsBioComo Inc. was planning to develop immunotherapy on May 18th '26.BioComo Inc. is currently developing this immunotherapy with the aim of commercializing it for highly malignant cancers characterized by a high number of CAFs.

NewsBioComo Inc. is developing vaccine production platform.In recent years, the world has been exposed to the threat of various emerging infectious diseases, and in order to overcome this threat, Mie University and BioComo Inc. (CEO: Masayuki Fukumura) have been working to develop a vaccine production platform against emerging infectious diseases, using a novel viral vector technology.